This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Subtype-specific biomarker validation in ovarian cancer	<p>Studies in human tumor samples suggest that the validation of ovarian carcinoma biomarkers should be performed on a subtype-specific basis. Most biomarker studies have not taken into account ovarian carcinoma subtypes. A retrospective analysis of ovarian carcinoma samples showed that biomarker expression profiles varied between the four ovarian cancer subtypes—serous, clear cell, endometrioid and mucinous. The analysis showed that only three of nine biomarkers associated with lower survival times in the overall cohort were applicable to serous carcinomas. The analysis also showed that Wilms tumor 1 (WT1) is associated with increased survival in serous carcinomas but decreased survival in the overall cohort. Next steps could include validating the subtype-specific markers in additional ovarian cancer patient cohorts.</p> <p>SciBX 2(2); doi:10.1038/scibx.2009.78 Published online Jan. 15, 2009</p>	Patent and licensing status unavailable	<p>Köbel, M. <i>et al. PLoS Med.</i>; published online Dec. 1, 2008; doi:10.1371/journal.pmed.0050232 Contact: David Huntsman, University of British Columbia, Vancouver, British Columbia, Canada e-mail: dhuntsma@bccancer.bc.ca</p>